Related Experiment Video
Updated: Apr 12, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.8K
Two macrocyclic polyamines as modulators of metal-mediated Aβ40 aggregation.
Yanfei Yang1, Tingting Chen, Shajun Zhu
1School of Chemistry and Chemical Engineering, Nantong University, Nantong, 226019, P. R. China. tingtingchenntu@163.com.
Summary
New chelators (L1 and L2) show promise in combating Alzheimer's disease (AD) by modulating metal-amyloid-beta (Aβ) interactions, reducing toxicity, and protecting against cell death.
Area of Science:
- Neuroscience
- Biochemistry
- Medicinal Chemistry
Background:
- Dysfunctional interactions between amyloid-beta (Aβ) and metal ions like Zn(2+) and Cu(2+) are implicated in Alzheimer's disease (AD) pathogenesis.
- Targeting these metal-Aβ interactions with chelators is a potential therapeutic strategy for AD.
Purpose of the Study:
- To investigate the efficacy of two cyclam derivatives, L1 and L2, in modulating metal-induced Aβ40 aggregation and associated neurotoxicity.
- To assess the potential of L1 and L2 as therapeutic agents for Alzheimer's disease.
Main Methods:
- Utilized BCA protein assay, thioflavin T fluorescence, and circular dichroism spectroscopy to analyze Aβ40 aggregation and structure.
- Conducted preliminary investigations using SH-SY5Y cells to evaluate neurotoxicity, reactive oxygen species (ROS) production, and apoptosis.
Main Results:
- L1 and L2 effectively inhibited Zn(2+)/Cu(2+)-induced Aβ40 aggregation.
- The chelators dissociated metal-Aβ40 aggregates and restored Aβ40 to a random coil conformation.
- L1 and L2 reduced metal-Aβ40 neurotoxicity, controlled ROS production, and protected cells from apoptosis.
Conclusions:
- Cyclam derivatives L1 and L2 demonstrate significant potential in disrupting pathogenic metal-Aβ interactions.
- These findings support further investigation of L1 and L2 as novel therapeutic candidates for Alzheimer's disease.
